中晚期肝癌患者应用TACE联合PMCT治疗的效果分析

摘要/Abstract

摘要： 目的探究中晚期肝癌患者应用TACE联合PMCT治疗的效果。方法 2018年3月—2020年4月宜兴市人民医院收治的中晚期肝癌患者60例,随机分为2组,每组30例,短间隔组患者TACE治疗同步PMCT治疗,长间隔组患者TACE治疗后1个月行PMCT治疗。于患者治疗3个月后比较临床疗效、甲胎蛋白、异常凝血酶原水平、2年生存率。结果短间隔组和长间隔组治疗后客观缓解率分别为43.33%、36.67%,2组治疗后客观缓解率比较差异均无统计学意义 (P>0.05)。治疗后,短间隔组血清甲胎蛋白、异常凝血酶原水平分别为[ (107.43±15.32)ng/mL、 (2831.26±118.50)mAU/mL];长间隔组血清甲胎蛋白、异常凝血酶原水平分别为[ (135.02±12.51)ng/mL、 (3135.65±107.28)mAU/mL],2组治疗后血清甲胎蛋白、异常凝血酶原低于治疗前,短间隔组更低 (P<0.05)。长间隔组和短间隔组2年总生存率分别为23.08%、46.43%,2组生存曲线比较差异有统计学意义 (P<0.05)。结论 TACE治疗同期行PMCT更有助于抑制中晚期肝癌患者的肿瘤因子表达,延长生存期,安全性良好。

关键词: 中晚期肝癌, 经肝动脉栓塞化疗, 经皮微波消融, 生存率

Abstract: Objective To explore the effect of combining TACE with PMCT in patients with advanced liver cancer.Methods From March 2018 to April 2020, 60 patients with advanced liver cancer admitted to Yixing People′s Hospital were randomly divided into two groups, with 30 patients in each groups. The patients in the short interval group received simultaneous treatment with TACE and PMCT. The patients in the long interval group received PMCT one month after TACE. After 3 months of treatment, the clinical efficacy, AFP, abnormal prothrombin levels and 2-year survival rate were compared. Results The objective remission rates of short interval group and long interval group after treatment were 43.33% and 36.67% respectively, and there was no significant difference between the two groups (P>0.05). After treatment, the levels of serum AFP and abnormal prothrombin in the short interval group were (107.43±15.32) ng/mL and (2831.26±118.50) mAU/mL, respectively. In the long interval group, the levels of serum AFP and abnormal prothrombin were (135.02±12.51) ng/mL and (3135.65±107.28) mAU/mL, respectively. Both groups showed lower levels of serum AFP and abnormal prothrombin after treatment compared to before treatment, with the short interval group showing a greater reduction (P<0.05).). The 2-year overall survival rates of the long interval group and the short interval group were 23.08% and 46.43%, respectively. The survival curves of the two groups were statistically different (P<0.05). Conclusion PMCT at the same time of TACE treatment is more helpful in inhibiting the expression of tumor factors in patients with advanced liver cancer, prolonging the survival period, and ensuring good safety.

Key words: Advanced liver cancer, TACE, PMCT, Survival rate

陈秀峰, 蒋丽萍, 沈玲. 中晚期肝癌患者应用TACE联合PMCT治疗的效果分析[J]. 肝脏, 2023, 28(9): 1068-1071.

CHEN Xiu-feng, JIANG Li-ping, SHEN Ling. Analysis of the effect of TACE combined with PMCT in patients with advanced liver cancer[J]. Chinese Hepatolgy, 2023, 28(9): 1068-1071.

参考文献

[1] 张慧贤, 马向明, 付庆江, 等. 经肝动脉化疗栓塞联合经皮微波消融序贯治疗中晚期肝癌的疗效及预后分析. 肝脏,2017,22(5):431-434.
[2] Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals (Basel),2021,14(1):36-39.
[3] Ando Y, Kawaoka T, Amioka K, et al. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma. Oncology,2021,99(8):507-517.
[4] 王卫刚, 王静, 杨慧. 经皮微波消融术前采用肝动脉化疗栓塞术(TACE)对老年肝癌的临床疗效和安全性观察. 贵州医药,2020,44(12):1949-1950.
[5] 唐定, 胡智强, 邓洲子, 等. 经导管肝动脉化疗栓塞术联合经皮穿刺微波消融术对肝癌患者血清AFP、CEA、CA19-9水平的影响. 癌症进展,2019,17(23):2800-2802.
[6] 卞锦花, 达婷, 罗建梅, 等. 超声引导下经皮微波消融联合肝动脉化疗栓塞治疗原发性肝癌的疗效观察. 中华实用诊断与治疗杂志,2020,34(5):509-512.
[7] 封冰, 王伟, 翟景明, 等. 中晚期肝癌应用微波消融联合经肝动脉化疗栓塞术的疗效及其对免疫功能、AFP、生存期的影响. 肝胆外科杂志,2021,29(2):142-145.
[8] Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol,2018,10(7):485-495.
[9] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版). 解放军医学杂志,2015,40(11):865-872.
[10] Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1-Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer,2016,62(3):138-145.
[11] Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute′s patient-reported outcomes version of the common terminology criteria for adverse events. Am Soc Clin Oncol Educ Book,2016,35(1):67-73.
[12] Huh J, Kim B, Lee J H, et al. Added value of CT arterial subtraction images in liver imaging reporting and data system treatment response categorization for transcatheter arterial chemoembolization-treated hepatocellular carcinoma. Invest Radiol,2021,56(2):109-116.
[13] 李猛, 陆荫英, 董景辉, 等. 经肝动脉化疗栓塞术联合微波消融治疗中晚期原发性肝癌的效果分析. 临床肝胆病杂志,2020,36(12):2720-2724.
[14] 顾星石, 白旭明, 程龙, 等. 经皮微波消融术前采用肝动脉化疗栓塞术对老年肝癌的临床疗效分析. 中华老年医学杂志,2019,38(8):885-888.
[15] 侯春光, 陶桢, 潘燕, 等. TACE联合PMCT治疗巨块型肝癌的效果分析. 中国现代普通外科进展,2018,21(4):311-313.
[16] 舒强, 刘小玲, 杨小李, 等. 经导管肝动脉化疗栓塞术联合经皮微波消融治疗复发性肝癌的预后分析. 中国普通外科杂志,2020,29(1):11-18.
[17] 魏健体. 腔内导管射频消融联合TACE对原发性肝癌患者门静脉癌栓的疗效及安全性分析. 肝胆外科杂志,2021,29(2):132-135.
[18] 李广俊, 蔡日, 游焜. 经皮微波消融治疗中晚期肝癌的疗效观察. 安徽医学,2021,42(6):669-674.